drugset / Trial / NCT02011321

Clevidipine for Vasospasm After Subarachnoid Hemorrhage (SAH)

NCT02011321

Phase 2 Withdrawn Henry Ford Health System
NaSingle-groupOpen-labelTreatment

Summary

Vasospasm occurs frequently after aneurysmal subarachnoid hemorrhage and can lead to strokes. The investigators will investigate if infusion of a novel drug, clevidipine, will decrease vasospasm during the infusion and post infusion period using transcranial doppler monitoring of patients with subarachnoid hemorrhage and moderate severity vasospasm

Timeline

Start
2014-03
Primary completion
2018-03
Completion
2018-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Clevidipine Small molecule Intravenous